Janux Therapeutics

Janux Therapeutics, Inc. operates a preclinical stage biopharmaceutical company which engages in developing therapeutics based on the Tumor Activated T Cell Engager platform technology. The company was founded in June 2017 and is headquartered in San Diego, CA.

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Janux Therapeutics, Inc. (JANX) came out with a quarterly loss of $0.42 per share versus the Zacks Consensus Estimate of a loss of $0.49. This compares to loss of $0.32 per share a year ago.

Janux Therapeutics, Inc. (JANX) Reports Q1 Loss, Tops Revenue Estimates

SAN DIEGO--(BUSINESS WIRE)---- $JANX--Janux Therapeutics, Inc. (Nasdaq: JANX) (Janux), a clinical-stage biopharmaceutical company developing a broad pipeline of novel immunotherapies by applying its proprietary technology to its Tumor Activated T Cell Engager (TRACTr) and Tumor Activated Immunomodulator (TRACIr) platforms, today reported financial results for the first quarter ended March 31, 2023 and provided a business update. “Janux hit a major milestone in the first quarter as we brought our second T.

Janux Therapeutics Reports First Quarter 2023 Financial Results and Business Highlights

Janux Therapeutics, Inc. (JANX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Analysts Estimate Janux Therapeutics, Inc. (JANX) to Report a Decline in Earnings: What to Look Out for

SAN DIEGO--(BUSINESS WIRE)---- $JANX--Janux Therapeutics to Participate at Upcoming May 2023 Investor Conferences.

Janux Therapeutics to Participate at Upcoming May 2023 Investor Conferences

SAN DIEGO--(BUSINESS WIRE)---- $JANX--Janux Therapeutics Announces First Patient Dosed with JANX008 in First-in-Human Phase 1 Clinical Trial in Patients with Solid Tumors

Janux Therapeutics Announces First Patient Dosed with JANX008 in First-in-Human Phase 1 Clinical Trial in Patients with Solid Tumors

Agios Pharmaceuticals

Veracyte

Verona Pharma

Adicet Bio, Inc.

OmniAb Inc

Sol-Gel Technologies

While the concept of high-risk speculation seems particularly dangerous at this juncture, gamblers may nevertheless want to consider the merits of targeting potentially lucrative biotech stocks that could be the next big thing. These lesser-known enterprises may not command worldwide attention at the moment.

7 Biotech Stocks That Could Be the Next Big Thing

SAN DIEGO--(BUSINESS WIRE)---- $JANX--Janux Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Business Highlight

Janux Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Business Highlights

SAN DIEGO--(BUSINESS WIRE)---- $JANX--Janux Therapeutics, Inc.

Janux Therapeutics to Participate in Novel IO Panel Discussion at Cowen's 43rd Annual Health Care Conference

Janux Therapeutics, Inc. (JANX) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.

Janux Therapeutics, Inc. (JANX) Surges 5.9%: Is This an Indication of Further Gains?

Janux Therapeutics, Inc. (JANX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).

Janux Therapeutics, Inc. (JANX) Upgraded to Strong Buy: What Does It Mean for the Stock?

SAN DIEGO--( BUSINESS WIRE )--Janux Therapeutics, Inc. (Nasdaq: JANX) (Janux), a clinical-stage biopharmaceutical company developing a broad pipeline of novel immunotherapies by applying its proprietary technology to its Tumor Activated T Cell Engager (TRACTr) and Tumor Activated Immunomodulator (TRACIr) platforms, today announced that the Company has submitted the investigational new drug (IND) application for JANX008 to the U.S. Food and Drug Administration, an EGFR-TRACTr in development for the treatment of EGFR-expressing solid tumors, including non-small cell lung cancer (NSCLC), colorectal cancer (CRC), renal cell carcinoma (RCC), and squamous cell carcinoma of the head and neck (SCCHN).

Janux Therapeutics Announces Submission of Investigational New Drug Application for JANX008, an EGFR-TRACTr for Solid Tumors

After losing some value lately, a hammer chart pattern has been formed for Janux Therapeutics, Inc. (JANX), indicating that the stock has found support. This, combined with an upward trend in earnings estimate revisions, could lead to a trend reversal for the stock in the near term.

Here's Why Janux Therapeutics, Inc. (JANX) Looks Ripe for Bottom Fishing

SAN DIEGO--( BUSINESS WIRE )--Janux Therapeutics, Inc. (Nasdaq: JANX) (Janux), a clinical-stage biopharmaceutical company developing a broad pipeline of novel immunotherapies by applying its proprietary technology to its Tumor Activated T Cell Engager (TRACTr) and Tumor Activated Immunomodulator (TRACIr) platforms, today announced that Janux management will present at two upcoming investor conferences and be available for 1x1 meetings. Details of the presentations are as follows:

Janux Therapeutics to Present at Upcoming Investor Conferences in November

GH Research PLC

Gemini Therapeutics

Omega Flex

Polar Power

Red Violet

Via Renewables

Throughout much of the new normal, the concept of short-squeeze stocks took off like wildfire. Essentially, this tactic centers on taking a contrarian bet against bearish traders in Wall Street's version of playing chicken.

7 Short-Squeeze Stocks for Bold Contrarians to Consider

SAN DIEGO--( BUSINESS WIRE )--Janux Therapeutics, Inc. (Nasdaq: JANX) (Janux), a clinical-stage biopharmaceutical company developing a broad pipeline of novel immunotherapies by applying its proprietary technology to its Tumor Activated T Cell Engager (TRACTr) and Tumor Activated Immunomodulator (TRACIr) platforms, today reported financial results for the third quarter ended September 30, 2022, and provided a business update.

Janux Therapeutics Reports Third Quarter 2022 Financial Results and Business Highlights

The clinical-stage biotech company just began its first clinical trial.

Why Janux Therapeutics Shares Rose 33.1% This Week

SAN DIEGO--(BUSINESS WIRE)---- $JANX--Janux Therapeutics Announces First Patient Dosed with JANX007 in First-in-Human Phase 1 Clinical Trial in Patients with Prostate Cancer

Janux Therapeutics Announces First Patient Dosed with JANX007 in First-in-Human Phase 1 Clinical Trial in Patients with Prostate Cancer

Cricut

Loop Industries

Olink Holding AB

Vigil Neuroscience

Short-squeeze stocks offer tremendous upside potential for people who laugh in the face of danger. Fundamentally, the concept involves betting against the pessimistic crowd with the aim of sparking a reactionary panic.

7 Short-Squeeze Stocks to Buy for Contrarian Investors

SAN DIEGO--(BUSINESS WIRE)---- $JANX--Janux Therapeutics, Inc. (Nasdaq: JANX) (Janux), a biopharmaceutical company developing a broad pipeline of novel immunotherapies by applying its proprietary technology to its Tumor Activated T Cell Engager (TRACTr) and Tumor Activated Immunomodulator (TRACIr) platforms, today announced the appointment of Brenda Van Vreeswyk as Head of Human Resources (HR). Ms. Van Vreeswyk brings extensive HR leadership and operations expertise across the life sciences industry, inc

Janux Therapeutics Appoints Brenda Van Vreeswyk as Head of Human Resources

SAN DIEGO--(BUSINESS WIRE)---- $JANX--Janux Therapeutics, Inc. (Nasdaq: JANX) (Janux), a biopharmaceutical company developing a broad pipeline of novel immunotherapies by applying its proprietary technology to its Tumor Activated T Cell Engager (TRACTr) and Tumor Activated Immunomodulator (TRACIr) platforms, today announced the appointment of Winston Kung to the Company's Board of Directors. Janux also announced that Stefan Heller, Ph.D., who has served on Janux's Board since 2018, has resigned. These ch

Janux Therapeutics Appoints Winston Kung to Board of Directors

SAN DIEGO--(BUSINESS WIRE)---- $JANX--Janux Therapeutics to Participate and Present at Upcoming Investor Conferences in September

Janux Therapeutics to Participate and Present at Upcoming Investor Conferences in September

SAN DIEGO--(BUSINESS WIRE)---- $JANX--Janux Therapeutics Reports Second Quarter 2022 Financial Results and Business Highlights

Janux Therapeutics Reports Second Quarter 2022 Financial Results and Business Highlights

SAN DIEGO--(BUSINESS WIRE)--Janux Therapeutics, Inc. (Nasdaq: JANX) (Janux), a biopharmaceutical company developing a broad pipeline of novel immunotherapies by applying its proprietary technology to its Tumor Activated T Cell Engager (TRACTr) and Tumor Activated Immunomodulator (TRACIr) platforms, today announced that Janux management will present at the 2022 Jefferies Global Healthcare Conference on Friday, June 10, 2022 at 11:00 a.m. ET in New York, New York. A live webcast of the presentati

Janux Therapeutics to Present at 2022 Jefferies Global Healthcare Conference

SAN DIEGO--(BUSINESS WIRE)--Janux Therapeutics, Inc. (Nasdaq: JANX) (Janux), a biopharmaceutical company developing a broad pipeline of novel immunotherapies by applying its proprietary technology to its Tumor Activated T Cell Engager (TRACTr) and Tumor Activated Immunomodulator (TRACIr) platforms, today announced that the U.S. Food and Drug Administration (FDA) has cleared the Company's investigational new drug (IND) application for its lead product candidate, JANX007, a PSMA-TRACTr in develop

Janux Therapeutics Announces FDA Clearance of Investigational New Drug Application for JANX007, a PSMA-TRACTr for Metastatic Castration-Resistant Prostate Cancer

SAN DIEGO--(BUSINESS WIRE)--Janux Therapeutics, Inc. (Nasdaq: JANX) (Janux), a biopharmaceutical company developing a broad pipeline of novel immunotherapies by applying its proprietary technology to its Tumor Activated T Cell Engager (TRACTr) and Tumor Activated Immunomodulator (TRACIr) platforms, today reported financial results for the first quarter ended March 31, 2022 and provided a business update. “Janux continues to make meaningful progress towards our goal of developing next-generation

News for Janux Therapeutics Stock (JANX)